-
公开(公告)号:US5817670A
公开(公告)日:1998-10-06
申请号:US776295
申请日:1997-01-30
申请人: Kazuhisa Takayama , Masahiro Iwata , Yoshinori Okamoto , Motonori Aoki , Akira Niwa , Yasuo Isomura
发明人: Kazuhisa Takayama , Masahiro Iwata , Yoshinori Okamoto , Motonori Aoki , Akira Niwa , Yasuo Isomura
IPC分类号: C07D471/04 , A61K31/435
CPC分类号: C07D471/04
摘要: 1,8-Naphthyridine derivatives represented by the following general formula (I), salts thereof, hydrates thereof and solvates thereof. ##STR1## They have an activity to inhibit type IV phosphodiesterase and are useful as agents for the prevention and treatment of respiratory diseases, inflammatory diseases accompanying organ transplantation, systemic or local arthropathy, proliferative diseases, micturition-related diseases and diseases in which tumor necrosis factor (TNF) and other cytokine (IL-1, IL-6 or the like) are concerned.
摘要翻译: PCT No.PCT / JP95 / 01700 Sec。 371日期1997年1月30日 102(e)日期1997年1月30日PCT 1995年8月28日PCT公布。 公开号WO96 / 06843 日期:1993年3月7日,由以下通式(I)表示的8-萘啶衍生物,其盐,其水合物和溶剂化物。 可用作预防和治疗呼吸系统疾病,伴随器官移植的炎性疾病,全身或局部关节病,增殖性疾病,排尿相关疾病和肿瘤坏死因子(TNF)等细胞因子(TNF-α) IL-1,IL-6等)。
-
公开(公告)号:US06174896B1
公开(公告)日:2001-01-16
申请号:US09312392
申请日:1999-05-14
申请人: Makoto Takeuchi , Ryo Naito , Masahiko Hayakawa , Yoshinori Okamoto , Yasuhiro Yonetoku , Ken Ikeda , Yasuo Isomura
发明人: Makoto Takeuchi , Ryo Naito , Masahiko Hayakawa , Yoshinori Okamoto , Yasuhiro Yonetoku , Ken Ikeda , Yasuo Isomura
IPC分类号: A61K31439
CPC分类号: C07D221/12 , C07D453/02 , C09K19/3444
摘要: Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same. The compound has an antagonistic effect on muscarinic M3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.
摘要翻译: 由通式(I)表示的喹喔啉衍生物,其盐,N-氧化物或季铵盐,以及含有它们的药物组合物。该化合物对毒蕈碱M3受体具有拮抗作用,可用作泌尿系统的预防或治疗 疾病,呼吸系统疾病或消化系统疾病。
-
公开(公告)号:US6017927A
公开(公告)日:2000-01-25
申请号:US860377
申请日:1997-08-28
申请人: Makoto Takeuchi , Ryo Naito , Masahiko Hayakawa , Yoshinori Okamoto , Yasuhiro Yonetoku , Ken Ikeda , Yasuo Isomura
发明人: Makoto Takeuchi , Ryo Naito , Masahiko Hayakawa , Yoshinori Okamoto , Yasuhiro Yonetoku , Ken Ikeda , Yasuo Isomura
IPC分类号: A61K31/439 , A61P1/00 , A61P11/00 , A61P11/06 , A61P13/00 , A61P13/10 , A61P29/00 , A61P31/00 , A61P43/00 , C07D221/12 , C07D453/02 , C07D471/04 , C09K19/34 , C09K19/40 , A61K31/435
CPC分类号: C07D221/12 , C07D453/02 , C09K19/3444
摘要: Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same. ##STR1## The compound has an antagonistic effect on muscarinic M.sub.3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.
摘要翻译: PCT No.PCT / JP95 / 02713 Sec。 371日期1997年8月28日 102(e)日期1997年8月28日PCT 1995年12月27日PCT PCT。 公开号WO96 / 20194 日本时间1997年7月4日由以下通式(I)表示的奎宁环衍生物,其盐,N-氧化物或季铵盐,以及含有它们的药物组合物。 该化合物对毒蕈碱M3受体具有拮抗作用,可用作泌尿系统疾病,呼吸系统疾病或消化系统疾病的预防或治疗。
-
公开(公告)号:US5538976A
公开(公告)日:1996-07-23
申请号:US325383
申请日:1994-10-26
申请人: Minoru Okada , Toru Yoden , Eiji Kawaminami , Yoshiaki Shimada , Masafumi Kudou , Yasuo Isomura
发明人: Minoru Okada , Toru Yoden , Eiji Kawaminami , Yoshiaki Shimada , Masafumi Kudou , Yasuo Isomura
IPC分类号: C07D237/20 , C07D239/42 , C07D253/06 , C07D253/07 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , A61K31/505
CPC分类号: C07D239/42 , C07D237/20 , C07D253/07 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/10 , C07D417/12 , C07D417/14
摘要: A substituted tertiary amino compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. They have an aromatase inhibiting activity and are useful as a prophylactic and/or therapeutic agent for breast cancer, mastopathy, endometriosis, prostatic-hypertrophy, and so forth.
摘要翻译: PCT No.PCT / JP93 / 00548 Sec。 371日期:1994年10月26日 102(e)日期1994年10月26日PCT提交1993年4月27日PCT公布。 公开号WO93 / 22290 日期:1993年11月11日(一)由通式(I)表示的取代叔氨基化合物或其药学上可接受的盐。 它们具有芳香酶抑制活性,可用作乳腺癌,乳腺病,子宫内膜异位症,前列腺肥大等的预防和/或治疗剂。
-
5.
公开(公告)号:US5480875A
公开(公告)日:1996-01-02
申请号:US360701
申请日:1994-12-21
IPC分类号: A61K31/675 , C07F9/6561 , C07D471/04
CPC分类号: C07F9/6561
摘要: Crystal D or E of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane -1,1-bis(phosphonic acid) monohydrate having specified lattice spacing and relative intensity in the powder X-ray diffraction spectrum obtained by using Cu-K.alpha. radiation and a dehydration peak temperature of 135.degree. to 149.degree. C. or 160.degree. to 170.degree. C. according to TG-DSC thermogravimetric analysis; and to a solid pharmaceutical preparation containing the same. The crystals are useful for producing a stable solid pharmaceutical preparation of the above compound which has an excellent drug efficacy for diseases wherein increased bone resorption participates, such as osteoporosis.
摘要翻译: PCT No.PCT / JP93 / 00821 Sec。 371日期1994年12月21日 102(e)日期1994年12月21日PCT提交1993年6月18日PCT公布。 出版物WO94 / 00462 日期:1994年1月6日。具有指定晶格间距的1-羟基-2-(咪唑并[1,2-a]吡啶-3-基)乙烷-1,1-双(膦酸)一水合物的晶体D或E, 根据TG-DSC热重分析,通过使用Cu-Kα辐射获得的粉末X射线衍射光谱中的相对强度和135℃至149℃或160℃至170℃的脱水峰温度; 和含有该制剂的固体药物制剂。 所述晶体可用于制备上述化合物的稳定的固体药物制剂,其对增加的骨吸收参与的疾病如骨质疏松症具有优异的药物功效。
-
公开(公告)号:US5442110A
公开(公告)日:1995-08-15
申请号:US211934
申请日:1994-04-20
申请人: Yasuo Isomura , Seijiro Akamatsu , Toru Yoden , Masafumi Kudou , Akira Suga
发明人: Yasuo Isomura , Seijiro Akamatsu , Toru Yoden , Masafumi Kudou , Akira Suga
IPC分类号: A61K31/165 , A61K31/19 , A61K31/215 , A61K31/265 , A61P1/02 , A61P27/02 , A61P29/00 , A61P43/00 , C07C237/22 , C07C259/06 , C07C323/57 , C07C323/60 , C07C327/30 , C07C327/32 , C07C327/34
CPC分类号: C07C259/06 , C07C237/22 , C07C323/57 , C07C323/60 , C07C327/30 , C07C327/32 , C07C327/34
摘要: ##STR1## A compound represented by general formula (I), a pharmaceutical composition containing same, a process for the production thereof, and an intermediate therefor. In formula (I) R
1 represents lower alkyl which may be substituted by a substituent selected from the group consisting of mercapto, lower alkylthio, arylthio and lower acylthio; R
2 , R
3 and R
4 may be the same or different from one another and each represents lower alkyl; X represents oxygen or sulfur; and Y represents a single bond or lower alkylene. The compound (I) has a matrix metalloprotease inhibitory activity and is useful for preventing and treating diseases caused by the progress of connective tissue breakage.摘要翻译: PCT No.PCT / JP92 / 01421 Sec。 371日期1994年04月20日 102(e)1994年4月20日PCT 1994年11月2日PCT PCT。 出版物WO93 / 09090 日期:1993年5月13日,由通式(I)表示的化合物,含有该化合物的药物组合物,其制备方法及其中间体。 在式(I)中,R 1表示可以被选自巯基,低级烷硫基,芳硫基和低级酰硫基的取代基取代的低级烷基; R2,R3和R4可以相同或不同,各自表示低级烷基; X表示氧或硫; Y代表单键或低级亚烷基。 化合物(I)具有基质金属蛋白酶抑制活性,可用于预防和治疗由结缔组织破裂进展引起的疾病。
-
公开(公告)号:US4251533A
公开(公告)日:1981-02-17
申请号:US67918
申请日:1979-08-20
申请人: Kazuo Kubo , Noriki Ito , Isao Souzu , Yasuo Isomura , Hiroshige Homma , Masuo Murakami
发明人: Kazuo Kubo , Noriki Ito , Isao Souzu , Yasuo Isomura , Hiroshige Homma , Masuo Murakami
IPC分类号: A61K31/44 , C07D213/64 , C07D213/74 , C07D213/89 , C07D455/02 , C07D471/04 , C07D498/04 , C07D513/04 , A61K31/435 , C07D471/02
CPC分类号: C07C255/00 , C07D213/64 , C07D213/89 , C07D471/04 , C07D513/04
摘要: Novel nitrogen-containing heterocyclic compounds shown by the formula ##STR1## wherein one of R.sub.1 and R.sub.2 represents a lower alkyl group, a phenyl group, a halophenyl group, or a lower alkoxyphenyl group and the other of them represents a hydrogen atom, a lower alkyl group, or a phenyl lower alkyl group; said R.sub.1 and R.sub.2 may combine with each other to form a trimethylene group or a tetramethylene group; R.sub.3 represents a hydrogen atom, a lower alkyl group, a phenyl group, or a phenyl lower alkyl group; X represents an oxygen atom, a sulfur atom, an imino group, or a group shown by ##STR2## wherein m represents 1 or 2 and R.sub.4 represents a lower alkyl group, a hydroxy lower alkyl group, a cycloalkyl group or a phenyl lower alkyl group; and Y represents an ethylene group which may be substituted by lower alkyl group, a trimethylene group, a tetramethylene group, a vinylene group which may be substituted by a lower alkyl group, or ##STR3## wherein R.sub.5 represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, or a phenyl group; said X is the group shown by ##STR4## when one of said R.sub.1 and R.sub.2 is a lower alkyl group and the other is a hydrogen atom, and said Y is an ethylene group, 1/7and the pharmacologically acceptable non-toxic salts thereof.The compounds described above are strong analgesic anti-inflammatory agents.
摘要翻译: 式中,R 1和R 2中的一个表示低级烷基,苯基,卤代苯基或低级烷氧基苯基,另一方表示氢原子,低级 烷基或苯基低级烷基; 所述R1和R2可以相互结合形成三亚甲基或四亚甲基; R3表示氢原子,低级烷基,苯基或苯基低级烷基; X表示氧原子,硫原子,亚氨基或由下式表示的基团,其中m表示1或2,R4表示低级烷基,羟基低级烷基,环烷基或苯基低级烷基 组; Y表示可以被低级烷基,三亚甲基,四亚甲基,可被低级烷基取代的亚乙烯基取代的亚乙基,或者R5表示氢原子的低级烷基 基,三氟甲基或苯基; 当所述R 1和R 2中的一个为低级烷基且另一个为氢原子,所述Y为亚乙基时,X为
所示的基团,其药理学上可接受的无毒性盐 。 上述化合物是强镇痛抗炎剂。 -
公开(公告)号:US4198512A
公开(公告)日:1980-04-15
申请号:US925217
申请日:1978-07-17
申请人: Kazuo Kubo , Noriki Ito , Isao Souzu , Yasuo Isomura , Hiroshige Homma
发明人: Kazuo Kubo , Noriki Ito , Isao Souzu , Yasuo Isomura , Hiroshige Homma
IPC分类号: A61K31/47 , A61K31/472 , A61P25/04 , A61P29/00 , C07D217/24
CPC分类号: C07D217/24
摘要: Novel 1-oxo-1,2-dihydroisoquinoline compounds of the formula ##STR1## wherein R.sub.1 represents a lower alkyl group or a phenyl lower alkyl group; R.sub.2 represents a lower alkyl group; R.sub.3 represents a hydrogen atom, a lower alkanoyl group, a lower alkyl group or a hydroxy lower alkyl group; and n is 0, 1 or 2 and the pharmacologically acceptable non-toxic salts thereof.The compounds of this invention are strong analgesic anti-inflammatory agents.
摘要翻译: 新颖的式Ⅰ-1-氧代-1,2-二氢异喹啉化合物,其中R1代表低级烷基或苯基低级烷基; R2表示低级烷基; R3表示氢原子,低级烷酰基,低级烷基或羟基低级烷基; 和n为0,1或2及其药理学上可接受的无毒盐。 本发明的化合物是强镇痛抗炎剂。
-
公开(公告)号:US5473100A
公开(公告)日:1995-12-05
申请号:US409709
申请日:1995-03-24
申请人: Yasuo Isomura , Seijiro Akamatsu , Toru Yoden , Masafumi Kudou , Akira Suga
发明人: Yasuo Isomura , Seijiro Akamatsu , Toru Yoden , Masafumi Kudou , Akira Suga
IPC分类号: A61K31/165 , A61K31/19 , A61K31/215 , A61K31/265 , A61P1/02 , A61P27/02 , A61P29/00 , A61P43/00 , C07C237/22 , C07C259/06 , C07C323/57 , C07C323/60 , C07C327/30 , C07C327/32 , C07C327/34 , C07C259/04
CPC分类号: C07C259/06 , C07C237/22 , C07C323/57 , C07C323/60 , C07C327/30 , C07C327/32 , C07C327/34
摘要: ##STR1## A compound represented by general formula (I), a pharmaceutical composition containing same, a process for the production thereof, and an intermediate therefor. In formula (I) R
1 represents lower alkyl which may be substituted by a substituent selected from the group consisting of mercapto, lower alkylthio, arylthio and lower acylthio; R
2 , R
3 and R
4 may be the same or different from one another and each represents lower alkyl; X represents oxygen or sulfur; and Y represents a single bond or lower alkylene. The compound (I) has a matrix metalloprotease inhibitory activity and is useful for preventing and treating diseases caused by the progress of connective tissue breakage.摘要翻译: 由通式(I)表示的化合物,含有该化合物的药物组合物,其制备方法及其中间体。 在式(I)中,R 1表示可以被选自巯基,低级烷硫基,芳硫基和低级酰硫基的取代基取代的低级烷基; R2,R3和R4可以相同或不同,各自表示低级烷基; X表示氧或硫; Y表示单键或低级亚烷基。 化合物(I)具有基质金属蛋白酶抑制活性,可用于预防和治疗由结缔组织破裂进展引起的疾病。
-
公开(公告)号:US5463064A
公开(公告)日:1995-10-31
申请号:US238537
申请日:1994-05-05
申请人: Kazuharu Tamazawa , Tadao Kojima , Hideki Arima , Yukiyasu Murakami , Yasuo Isomura , Minoru Okada , Kiyoshi Takanobu , Toichi Takenaka
发明人: Kazuharu Tamazawa , Tadao Kojima , Hideki Arima , Yukiyasu Murakami , Yasuo Isomura , Minoru Okada , Kiyoshi Takanobu , Toichi Takenaka
IPC分类号: C07D207/24 , C07D211/90 , C07D401/12
CPC分类号: C07D401/12 , C07D207/24 , C07D211/90
摘要: A dextro-rotatory optical isomer of diastereoisomer A of (.+-.)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl)ester 5-methyl ester is provided having the formula ##STR1## and wherein the melting point of the hydrochloride of the dextro-rotatory optical isomer is 223.degree. to 230.degree. C. (decomp.), or a pharmaceutically acceptable acid addition salt thereof.
摘要翻译: (+/-) - 2,6-二甲基-4-(3-硝基苯基)-1,4-二氢吡啶-3,5-二羧酸3-(1-苄基吡咯烷-3-酮)的非对映异构体A的右旋旋光异构体 - 基)酯5-甲酯,其具有式“IMAGE”,其中右旋旋光异构体的盐酸盐的熔点为223〜230℃(分解),或药学上可接受的酸加成 的盐。
-
-
-
-
-
-
-
-
-